What is Lexicon Pharmaceuticals's stock issuance proceeds?

Lexicon Pharmaceuticals (LXRX) reported stock issuance proceeds of $69.99M in Q1 2026.

What is the long-term trend for Lexicon Pharmaceuticals's stock issuance proceeds?

Over 3 years (2021 to 2025), Lexicon Pharmaceuticals's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $36.4M to $0.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Lexicon Pharmaceuticals LXRX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Merck & Co.MRK

$157M+726%

CytokineticsCYTK

$11.35M—

Zevra Therapeutics, Inc.ZVRA

$752K—

Eton Pharmaceuticals, Inc.ETON

$1.39M+253%

Theravance BiopharmaTBPH

$241K+1,105%

Mineralys Therapeutics, Inc.MLYS

$4.06M-97.9%

Other financials

Income statement

See full

Revenue$21.1M+1,572%

Gross profit$21.0M+1,604%

Operating income-$996.0K+96.1%

Net income-$1.0M+95.9%

EPS (diluted)$0.00+100%

Balance sheet

See full

Cash & equivalents$67.1M+6.7%

Total debt$57.7M-45.7%

Total equity$202.9M+64.9%

Total assets$268.8M-9.7%

Cash flow

See full

Operating cash flow-$14.7M+66.4%

CapEx--100%

Free cash flow-$17.2M+21.5%

Valuation

See full

Market cap$986.12M+262%

Enterprise value$976.73M+209%

P/S14.2×+5.4×

Profitability

See full

Gross margin99.5%+1.5pp

Operating margin-34.8%-16.8pp

Net margin-37.5%-18.1pp

FCF margin-578.5%-283pp

Returns & leverage

See full

Return on equity-16%-7.2pp

Debt / equity0.3×-0.6×

Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Lexicon Pharmaceuticals's stock issuance proceeds?: Lexicon Pharmaceuticals (LXRX) reported stock issuance proceeds of $69.99M in Q1 2026.
What is the long-term trend for Lexicon Pharmaceuticals's stock issuance proceeds?: Over 3 years (2021 to 2025), Lexicon Pharmaceuticals's stock issuance proceeds has grown at a -100.0% compound annual growth rate (CAGR), from $36.4M to $0.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.